Search Results - "Gadner, H."

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 by Möricke, A, Zimmermann, M, Reiter, A, Henze, G, Schrauder, A, Gadner, H, Ludwig, W D, Ritter, J, Harbott, J, Mann, G, Klingebiel, T, Zintl, F, Niemeyer, C, Kremens, B, Niggli, F, Niethammer, D, Welte, K, Stanulla, M, Odenwald, E, Riehm, H, Schrappe, M

“…Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin–Frankfurt–Münster (BFM) study group for childhood…”
Get full text

Treatment of adult-onset Langerhans cell histiocytosis—is it different from the pediatric approach? by Gadner, H.

Get full text

The life and work of Professor Riehm from a participant's perspective by Gadner, H

Get more information

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia by Flohr, T, Schrauder, A, Cazzaniga, G, Panzer-Grümayer, R, van der Velden, V, Fischer, S, Stanulla, M, Basso, G, Niggli, F K, Schäfer, B W, Sutton, R, Koehler, R, Zimmermann, M, Valsecchi, M G, Gadner, H, Masera, G, Schrappe, M, van Dongen, J J M, Biondi, A, Bartram, C R

“…Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in…”
Get full text

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 by SCHRAPPE, M, REITER, A, ZIMMERMANN, M, HARBOTT, J, LUDWIG, W.-D, HENZE, G, GADNER, H, ODENWALD, E, RIEHM, H

“…Four thousand, four hundred and forty eligible children of up to 18 years of age were treated in four consecutive trials between 1981 and 1995 with the…”
Get full text

Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group by COTTERILL, S. J, AHRENS, S, PAULUSSEN, M, JÜRGENS, H. F, VOUTE, P. A, GADNER, H, CRAFT, A. W

“…To further elaborate on prognostic factors for Ewing's sarcoma of bone and to document improvements in relapse-free survival (RFS) and trends in local therapy…”
Get full text

Risk factors for diabetes insipidus in langerhans cell histiocytosis by Grois, N., Pötschger, U., Prosch, H., Minkov, M., Arico, M., Braier, J., Henter, J-I., Janka-Schaub, G., Ladisch, S., Ritter, J., Steiner, M., Unger, E., Gadner, H.

“…Background Diabetes insipidus (DI) is the most frequent central nervous system (CNS)‐related permanent consequence in Langerhans cell histiocytosis (LCH),…”
Get full text

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials by Creutzig, U, Zimmermann, M, Ritter, J, Reinhardt, D, Hermann, J, Henze, G, Jürgens, H, Kabisch, H, Reiter, A, Riehm, H, Gadner, H, Schellong, G

“…A total of 1111 children with acute myeloblastic leukaemia (AML) were treated in four consecutive Berlin-Frankfurt-Münster (BFM) studies from 1978 to 1998. The…”
Get full text

Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors by Benesch, M., Windelberg, M., Sauseng, W., Witt, V., Fleischhack, G., Lackner, H., Gadner, H., Bode, U., Urban, C.

“…Background: The aim of this study was to evaluate feasibility and toxicity of bevacizumab (Avastin®), a monoclonal antibody directed against the vascular…”
Get full text

Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria by Rossig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., Reinhardt, D., Burkhardt, B., Woessmann, W., Zimmermann, M., Gadner, H., Mann, G., Schellong, G., Mauz-Koerholz, C., Dirksen, U., Bielack, S., Berthold, F., Graf, N., Rutkowski, S., Calaminus, G., Kaatsch, P., Creutzig, U.

“…In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease‐specific first‐line clinical trials or interim…”
Get full text

Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study by FELDER-PUIG, R, DI GALLO, A, WALDENMAIR, M, NORDEN, P, WINTER, A, GADNER, H, TOPF, R

“…The results of a 5-year longitudinal prospective study about the health-related quality of life (HRQL) of pediatric patients receiving allogeneic bone marrow…”
Get full text

Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86 by Paulussen, M, Ahrens, S, Dunst, J, Winkelmann, W, Exner, G U, Kotz, R, Amann, G, Dockhorn-Dworniczak, B, Harms, D, Müller-Weihrich, S, Welte, K, Kornhuber, B, Janka-Schaub, G, Göbel, U, Treuner, J, Voûte, P A, Zoubek, A, Gadner, H, Jürgens, H

“…Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone. We analyzed…”
Get full text

Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group by Prucker, C, Attarbaschi, A, Peters, C, Dworzak, M N, Pötschger, U, Urban, C, Fink, F-M, Meister, B, Schmitt, K, Haas, O A, Gadner, H, Mann, G

“…In the management of the childhood acute lymphoblastic leukemia (ALL), 5% of failures are due to induction death and treatment-related deaths in first complete…”
Get full text

Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia–Berlin-Frankfurt-Münster 93 by CREUTZIG, U, RITTER, J, REITER, A, KLUBA, U, NIGGLI, F, GADNER, H, ZIMMERMANN, M, REINHARDT, D, HERMANN, J, BERTHOLD, F, HENZE, G, JÜRGENS, H, KABISCH, H, HAVERS, W

“…To improve outcome in high-risk patients, high-dose cytarabine and mitoxantrone (HAM) was introduced into the treatment of children with acute myelogenous…”
Get full text

Validation of the German Version of the Pediatric Quality of Life Inventory™ (PedsQL™) in Childhood Cancer Patients off Treatment and Children with Epilepsy by R. Felder-Puig, Frey, E., K. Proksch, J. W. Varni, H. Gadner, R. Topf

“…The Pediatric Quality of Life Inventory™ (PedsQL™) is a relatively new instrument developed in the US to assess health-related quality of life (HRQL) in…”
Get full text

High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing’s Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation by BURDACH, S, MEYER-BAHLBURG, A, PAPE, H, GADNER, H, DUNST, J, JUERGENS, H, LAWS, H. J, HAASE, R, VAN KAIK, B, METZNER, B, WAWER, A, FINKE, R, GÖBEL, U, HAERTING, J

“…Risk stratification of metastatic and relapsed Ewing's tumors (ETs) has been a matter of debate during the last decade. Patients with bone or bone marrow…”
Get full text

Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer by Dohnal, A.M, Witt, V, Hügel, H, Holter, W, Gadner, H, Felzmann, T., MD

“…Background Cancer vaccines employing DC in their capacity as APC have been tolerated well and have shown some efficacy in clinical studies. IL-12, a cytokine…”
Get full text

Langerhans cell histiocytosis in neonates by Minkov, M., Prosch, H., Steiner, M., Grois, N., Pötschger, U., Kaatsch, P., Janka-Schaub, G., Gadner, H.

“…Background To study the incidence, clinical patterns, course, and outcome of neonatal Langerhans cell histiocytosis (LCH). Procedure Retrospective analysis of…”
Get full text

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation by MILLOT, F, GUILHOT, J, GUILHOT, F, SUTTORP, M, NELKEN, B, LEBLANC, T, DE BONT, E. S, BEKASSY, A. N, GADNER, H, SUFLIARSKA, S, STARY, J, GSCHJIDMEIER, H

“…A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia…”
Get full text

Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000 by Schrappe, M, Möricke, A, Reiter, A, Henze, G, Welte, K, Gadner, H, Ludwig, W-D, Ritter, J, Harbott, J, Mann, G, Klingebiel, T, Gruhn, B, Niemeyer, C, Kremens, B, Niggli, F, Debatin, K-M, Ratei, R, Stanulla, M, Beier, R, Cario, G, Schrauder, A, Zimmermann, M

“…Between 1981 and 2000, 6 609 children (<18 years of age) were treated in 5 consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood…”
Get more information